title: Model aims to reduce discrepancy between phase II, phase III trials.
authors.forename: T
authors.initials: T
authors.lastname: Reynolds
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001499:Bayes Theorem; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D015986:Confounding Factors, Epidemiologic; D017277:Drug Approval; D019317:Evidence-Based Medicine; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D015233:Models, Statistical; D009369:Neoplasms / Q000188:drug therapy*; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents